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ABSTRACT  
Background  
Screening for atrial fibrillation (AF) in people aged ≥65 years is recommended by international 
guidelines. The Atrial Fibrillation Screen, Management And guideline-Recommended Therapy (AF-
SMART) studies of opportunistic AF screening in 16 metropolitan and rural general practices were 
conducted from November 2016 - June 2019. These studies trialled custom-designed eHealth tools 
to support all stages of AF screening in general practice.  
Methods 
A realist evaluation of the AF-SMART studies, which aimed to explain the circumstances in which the 
program worked (or not) to increase the proportion of people screened for AF. The initial program 
theory was based on our previous research, policy documents and screening studies. To test this, we 
conducted 45 semi-structured interviews with general practitioners (GPs), nurses and practice 
managers across all participating practices, and collected observational and quantitative screening 
data. These data were analysed and interpreted to refine the program theory. 
Results  
GPs/nurses liked the eHealth tools, although technical problems sometimes disrupted screening. 
Time was the main barrier to screening for GPs/nurses, so systems need to be very efficient. 
Practices with leadership from a senior GP ‘screening champion’ had broader uptake, especially from 
the nursing team. Providing regular feedback on screening data was beneficial for quality 
improvement and motivation. Clear protocols for follow-up of abnormal results were required for 
successful nurse-led screening in a hierarchical system. Participation in the program had broader 
benefits of improving AF knowledge and raising the profile of cardiovascular health in the practice. 
Screening for a shorter, more intense period (eg during influenza vaccination) worked well for 
practices where sufficient staff time was allocated. 
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Conclusions 
Introducing an AF screening program is likely to be successful in contexts where there is a senior GP 
‘screening champion’, a clear protocol exists for abnormal results, and there is regular data reporting 
to staff. These contexts link to mechanisms around motivation, leadership, empowerment of nurses, 
and efficient screening systems. The contexts and mechanisms contribute to the longer-term 
outcomes of increasing the proportion of people screened and treated for AF, which is 
recommended by guidelines as a key strategy for the prevention of AF-related stroke. 
Trial registrations 
AF SMART (metropolitan): ACTRN12616000850471 (Australia New Zealand Clinical Trials Registry) 
AF SMART II (rural): ACTRN12618000004268 (Australia New Zealand Clinical Trials Registry) 
Keywords 
Atrial fibrillation, screening, realist evaluation, general practice, primary care 
 
BACKGROUND 
Gaps in AF screening and treatment 
Atrial fibrillation (AF) is the most common heart arrhythmia. The prevalence of AF increases with 
age, and if untreated, raises the risk of stroke fivefold (1). AF is commonly asymptomatic, and 
approximately 1.4% of people aged ≥65 years have undiagnosed AF (2). AF-related stroke is highly 
preventable with appropriate oral anticoagulant (OAC) treatment. For those at high risk of stroke 
(with a CHA2DS2-VA (3) risk score ≥2), OAC treatment can reduce the risk of stroke by 64% (4).  
A number of guidelines and expert consensus statements now recommend opportunistic single-
timepoint AF screening for people aged ≥65 years (1, 3, 5). These guidelines generally advocate 
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screening by pulse palpation or single-lead electrocardiogram (ECG). Despite these 
recommendations, screening is not routinely performed opportunistically in practice. A survey of 
general practitioners (GPs) published in The Economist found that respondents in Australia had only 
screened 11% of eligible patients in the previous fortnight (6). 
Historically, there were substantial gaps in treatment for patients diagnosed with AF. Treatment 
rates were previously around 50-60% (7) but are reported to be increasing in England, Spain and 
Denmark (8-10). These increases are largely due to the introduction of non-vitamin K dependent 
OAC (NOAC) drugs. 
The AF-SMART studies 
The Atrial Fibrillation Screen, Management And Guideline Recommended Therapy (AF-SMART) 
studies of opportunistic AF screening implementation in metropolitan (11) and rural (12) general 
practice were conducted by our research group from November 2016 - June 2019.  
These studies had very similar methods, which have been described previously (11, 12). Briefly, a 
convenience sample of 16 general practices (8 metropolitan and 8 rural) in New South Wales, 
Australia were recruited. Each practice was provided with several smartphone handheld single lead 
ECGs (iECG) (Kardia Mobile, Alivecor (13)), together with several custom-designed eHealth tools to 
support all stages of screening. These tools were: 
1. A screening prompt: this app was located on a third-party hosting platform and used 
information extracted in real-time from the electronic medical record to show a small 
screening prompt when an eligible patient’s file was opened. Eligible patients were those 
attending the practice who were aged ≥65 years with no previous AF diagnosis and who had 
not been screened with the iECG in the past 12 months. The visibility of the prompt was 
improved during the study based on user feedback. Practices also recorded the iECG 
automated result for each screening in this app. 
 
5 
 
2. Electronic Decision Support (EDS): the EDS app was also located on the same third-party 
platform and guided evidence-based treatment for those diagnosed with AF. The EDS used 
information from the patient’s electronic medical record to calculate the patient’s CHA2DS2-
VA score (3) and associated stroke risk, and made OAC treatment recommendations based 
on guidelines. 
 
3. Data reporting for Quality Improvement (QI): de-identified, custom-designed data extracts 
were obtained every 1-2 months from practices. Practices were then provided with regular 
QI reports of their AF screening data based on these data extracts. Information in these 
reports included the total number screened by each GP/nurse, the number of 
normal/abnormal results, the percentage of eligible patients screened, the number of 
confirmed cases of AF and the proportion of these treated according to guidelines. The level 
of detail provided in the QI reports was increased in the rural practices, in order to attract 
specific QI continuing professional development (CPD) points for GPs. 
Practices conducted screening for a median of 5 months (range: 2-12 months). Practice nurses and 
GPs were both able to screen patients. All follow-up of patients with abnormal screening results, 
including other diagnostic tests, management and whether specialist referral was required, was at 
the discretion of the treating GP. Some practices chose to undertake screening for shorter, more 
intense periods, e.g. during influenza (flu) vaccination clinics. Practices were reimbursed a small 
amount for screening (about AU$10 per patient screened, plus $1000 to cover IT costs and setup 
time) to mimic potential “real world” Medicare funding. 
Key study outcomes included: the proportion of eligible people screened for AF, and the proportion 
of people with AF treated according to guidelines. 
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Realist evaluation 
The realist evaluation framework seeks to build a program theory to identify the reasons 
interventions affect changes differently in different contexts. It is a theory-driven and method 
neutral evaluation framework based on a series of informed hypotheses developed for scientific 
research by Pawson and Tilly (14). Realist evaluation asks the key questions of ‘what works’, ‘for 
whom’ and ‘in what situation’. It analyses practices within the realm of interacting psychosocial and 
cultural systems, which consists of multiple actors, contexts, and mechanisms. Realist evaluation 
does not assume outcomes result directly from interventions, because the interaction between an 
intervention and an outcome can vary and produce a rippling effect that changes the outcomes at 
other levels of the system.  
Central to realist evaluation is the context (C) + mechanism (M) = outcome (O) formula as a guiding 
principle for enquiry. This configuration links logical models of interventions (mechanisms) with 
circumstances (contexts), with the aim to demonstrate the intricacies of the interconnected causal 
relationships that resulted in desired or unintended changes (outcomes). Contexts are conditions 
that a specific intervention operates in. Mechanisms are ‘generative’ and refer to a combination of 
interacting stakeholder reasoning and resources, which triggers stakeholder responses that result in 
an outcome. Outcomes are effects resulting from the conditions created by mechanisms operating 
in a context and comprise intended and unintended effects of a program. Just as there are multiple 
actors, contexts and mechanisms in place, realist evaluation uses multiple outcome measures to 
analyse a program’s success.  
Realist evaluation has been widely applied to public health and QI programs and healthcare 
interventions to explain outcome differences and to test and refine a program theory to determine 
how/why a program works. In particular, it has been used to assess complex healthcare programs 
aimed at behaviour changes and quality improvement, e.g. a UK quality improvement program to 
increase NOAC prescription for AF in general practice (15), an individual health intervention to 
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reduce pelvic floor prolapse for women (16), a local-level intervention to improve paediatric and 
neonatal clinical practices (17), and in a large government program to support normal birth (18). 
There are usually three phases in realist evaluation (19). These are:  
1. developing the initial program theory, which is tested and refined during the study; 
2. testing the program theory through mixed methods of data collection; and  
3. analysing data to refine the program theory and context-mechanism-outcome (CMO) 
configurations.  
Realist evaluations often use multiple data sources. The overall aim is for the data to “allow analysis 
of CMOs relevant to the program theory and to the purposes of and the questions for the 
evaluation”(20). A mixed-methods approach is often used, including both quantitative data (e.g. 
surveys or clinical audit data) and qualitative data (e.g. focus groups, semi-structured interviews) 
sources (21). Evaluation of complex programs requires more thorough analysis of implementation 
contexts. The success of a program or intervention often depends on individual responses as well as 
the wider context (20), and interview data can allow researchers to provide a deeper level of 
understanding. For example, semi-structured interviews of GPs, nurses and practice managers 
provided detail about the dynamics of primary care practices, underlying financial or non-financial 
motivations, AF knowledge, and clinical staff views on patient preferences, providing a more 
nuanced understanding of the contexts in which the AF screening program was operating. The 
evaluation was conducted concurrently with the AF-SMART studies, from November 2016 – June 
2019 and aimed to describe and explain the circumstances in which the AF screening program 
(including the custom designed eHealth tools) worked (or not) to increase the proportion of eligible 
people screened for AF. 
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METHODS 
Phase 1: developing the initial program theory  
The initial program theory was developed using a number of sources. These sources included: a 
review of findings in previous studies of AF screening; discussions with stakeholders (GPs, practice 
nurses, researchers and cardiologists); and examination of data and findings from our previous AF 
screening pilot studies (22, 23).  
Phase 2: testing the program theory 
The initial program theory was tested by collecting data during the AF-SMART studies. Primary 
modes of data collection were semi-structured interviews, observation and quantitative screening 
data. 
Semi-structured interviews 
Semi-structured interviews were conducted with 45 staff (21 GPs, 13 nurses and 11 practice 
managers) across each study site towards the end of the study period in that practice.  A purposive 
sampling approach was used, and at each practice we sought to interview GPs and nurses who had 
participated in the screening program, ideally including some staff who had done small numbers and 
some who had done large numbers of screenings to obtain a range of views. Written informed 
consent was obtained from each subject prior to the interview.  
Interviews explored participants’ views on the screening program, iECG device, electronic tools (the 
screening prompt and EDS), deidentified quantitative data collection and QI reporting. GPs and 
nurses were asked to discuss their views on various barriers and enablers to screening, including: 
confidence in performing screening, how long it took, their impression of whether patients liked the 
screening process, how abnormal results were dealt with and treatment of those diagnosed with AF 
(Supplementary Table 1). The interviews were audio recorded and transcribed verbatim. 
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Observation 
We observed staff at practices during the AF-SMART studies. Observation followed an ethnographic 
approach (24) and occurred during practice visits and through phone calls and emails with practice 
staff, GPs and nurses. Key points for observation included barriers and enablers to screening, 
attitudes to the value of screening and the level of motivation to participate. Observational data 
were recorded in all practices (n=8) using field notes and researcher reflective diaries and were 
analysed together with transcripts of semi-structured interviews using an inductive thematic 
framework approach, as described below. Our data from observations, together with the interview 
and quantitative data, assisted in creating a deeper understanding of the causal pathways linking the 
complex processes (24)  involved in the screening program. 
Quantitative screening data 
Quantitative screening data were obtained every 1-2 months from each participating practice using 
a customised, deidentified clinical audit tool. Data included the number of screenings done by each 
GP/nurse, the iECG automated interpretation, details of AF diagnoses and treatment, most recent 
visit date to the practice and some demographic data. These data extracts were used to report back 
to practices about their study progress, and formed part of a QI clinical audit (eligible for CPD points) 
in the AF SMART rural study. 
Phase 3: Refining the program theory 
Semi-structured interviews 
Semi-structured interview transcripts, together with observation field notes and researcher 
reflective diaries, were analysed using a thematic framework approach. This approach classifies data 
according to key themes, commonalities and patterns (25, 26). An inductive process was used to 
construct the coding framework based on the four initial interviews, which was then used to 
systematically code the remaining interview transcripts by two members of the research team. 
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Refinements and additions were made to the framework as required until thematic saturation was 
reached, i.e. when no new themes or codes emerged (27). These data were iteratively reflected on, 
shared and discussed with the broader research team to refine the CMO configurations and key 
propositions. 
Quantitative screening data 
Screening data at each practice were analysed to show the number people screened during the 
study and the proportion of eligible patients screened who attended the practice during the study 
period. These data were then used to show the overall ‘success’ of each practice and were linked to 
refined CMO configurations and key propositions (Table 1). 
Ethical approval 
The AF-SMART studies had approval from the University of Sydney Human Research Ethics 
Committee (Protocol No. 2017/1017 and Protocol No. 2014/962). 
This paper has been written to comply with the RAMESES II reporting standards for realist evaluation 
(20).  
RESULTS 
Phase 1: Initial program theory 
Essentially, the findings of phase I of the evaluation were that many individual screening tools do not 
work very well in isolation and that a comprehensive and efficient system is needed. In relation to 
screening, our previous studies showed both GPs and nurses liked screening with the iECG device, 
but that there were several key barriers, including time pressure (both for screening and follow-up 
of abnormal results), and lack of funding/remuneration for screening (22, 23). In relation to 
treatment of patients with AF, a range of interventions have been developed to increase effective 
prescribing of guideline-recommended anticoagulation in primary care settings. These include use of 
electronic decision support tools (28), targeted GP-education programs (29), nurse-led clinics (30), 
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and patient-focused education interventions (31). Overall, these interventions increase effective 
prescribing, but the results are varied and may decrease over time (31). 
Therefore, our initial program theory was that by providing a novel screening device (the iECG) 
together with integrated electronic tools (including a screening prompt to automatically identify 
eligible patients) and financial incentives to support all stages of screening, the program will be more 
systematic and efficient, and therefore time-poor GPs and nurses will opportunistically screen a 
higher proportion of eligible patients aged ≥65 years seen in the practice (Figure 1). Guidelines  and 
expert consensus (1, 3, 5, 32) recommend increasing screening (and treatment), including in the 
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primary care setting, to prevent more strokes.
 
Figure 1 – initial program theory  
AF, atrial fibrillation; EDS, electronic decision support; iECG, smartphone electrocardiograph; CPD, continuing professional 
development; QI, quality improvement  
 
Phase 2: Testing the program theory: key propositions 
Seven key propositions were identified based on key themes emerging from the data collected in 
phase 2 (Figure 2): 
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Proposition 1: Most GPs, nurses and patients liked the novel eHealth tools, especially the iECG device 
and improved prompts  
All GPs and nurses interviewed stated that they liked the iECG device. They also reported a high level 
of patient satisfaction with the device. The real-time trace on the smartphone screen together with 
the automated interpretation were engaging, and the device was cutting-edge, which participating 
GPs felt reflected well on the practice: 
“The patients really quite enjoyed it and I quite enjoyed playing with a little machine too. I 
quite enjoyed the technology side of it.” (GP 1, Practice A) 
“Patient acceptability has been really high…it’s so easy and quick” (GP 1, Practice C)   
“I think it’s very encouraging…to get an ECG rhythm strip and look at it immediately to see a 
regular heart rhythm.” (GP 2, Practice C)   
“Patients absolutely loved it. Everyone loves new technology and…. It reflects well on me in a 
sense.” (GP 1, Practice I) 
All except one of the interviewees were very confident using the device and performing screening, 
partly due to the ubiquity of smartphones.  
“I felt confident. It was very easy to do.” (Nurse, Practice A)  
The only difficulty with the iECG was taking a reading for people with a tremor or arthritic fingers: 
“The only difficulty was with the elderly with tremors. They got to a certain age, probably 
about 85, where they just couldn’t…it was almost like a screen for cognitive status.” (GP 2, 
Practice A)  
“Some of them had essential tremor…I just couldn’t get a tracing.” (GP 1, Practice I) 
A minority of interviewees (less than a quarter) reported resistance to technology, either in relation 
to their own attitudes or as a perceived barrier to uptake at their practice: 
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“I’m probably technically challenged sometimes…I don’t want to push any wrong buttons.” 
(Nurse, Practice P)  
“Some GPs are uncomfortable and uncertain with new technology.” (GP 1, Practice I) 
The improved prompt was a useful tool for nurses and GPs who participated in screening, and meant 
that they did not forget about screening: 
“The prompt was very useful…it reminded me to [screen].” (GP 1, Practice A) 
 
Proposition 2: Time was the main barrier to screening for GPs/nurses who have little control over their 
time. Systems need to be very efficient, and reliability is key with eHealth tools 
More than three-quarters of respondents indicated that time was the main barrier to AF screening in 
general practice. This was the case even for GPs and nurses who were generally very motivated. 
Importantly, screening was always done as an ‘adjunct’ task – that is, it was not the main reason 
patients were at the practice – and therefore, it added time to the consultation. Beyond a certain 
point, performing screening risked ‘hijacking the consultation’:  
“It was something to be done on quieter days, not horrendous clinical days… when we were 
running behind time, you tended not to get the screening done because it was on top of what 
the consultation was about.” (GP, Practice H)  
GPs and particularly nurses both had relatively little control over their time:   
“The nurses’ schedule seems to be so hectic they did what they could…it's more like a mini 
emergency room at times so it made it difficult.” (Practice Manager, Practice P)  
“[Patients have] their own list of things that we’ve got to get through and then we’ve got a 
couple of things that we might need to do urgently, so it was often a struggle to find the time 
to do it.” (GP 2, Practice I)  
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In this context, systems need to be very efficient and electronic tools need to work well, otherwise 
they add time. There were some reliability issues with the eHealth tools, which interrupted 
screening and undermined trust in the electronic tools. 
“When it works it's great, and I love all the things. It’s just so unreliable…that unless you've 
got someone like me who really is willing to give it a go…[others] don't have the time.” (GP, 
Practice E) 
“[the prompt and EDS] wouldn’t work for quite a while, and then the phone wouldn’t work 
for some reason. It was fixed eventually.” (GP 1, Practice A)  
While the iECG device was quick to use, often extra time was required to explain the device, 
screening process and rationale to the patients took extra time, particularly compared to pulse 
palpation. 
“I could take a pulse for 30 seconds or I could spend 3 minutes explaining to them the device 
and where to put their fingers and telling them what we were going to do. That’s the 
difference…as far as time use.” (Nurse, Practice H) 
“It took 5-10 minutes because it meant you did a lot more talking about preventative stuff, 
explaining things.” (GP, Practice H)  
 
Proposition 3: Leadership: having a senior GP as a ‘screening champion’ increases uptake across the 
practice especially from the nursing team 
In most practices, a small number of GPs were very engaged with the program and screened a lot of 
people themselves. Usually, these were senior GPs (eg a partner in the practice), and when they 
provided this leadership, i.e. acting as a ‘screening champion’, there was broader uptake in 
screening across the practice, especially from the nursing team. The GP champion provided 
leadership and increased motivation, as well as reinforcing the idea of practice-level participation:  
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“A couple of GPs really took it on, while a couple of them found it a burden. [A GP champion] 
spoke to them and said ‘we really need to be doing this’.” (Nurse, Practice A)  
Nurses also performed better when there was a GP champion as well as a nursing team leader 
providing leadership with screening:  
“We work together and we just say ‘oh that’s right we do that’, so usually we can work through 
[problems].” (Nurse, Practice P)  
“I don’t feel motivated to do it because nobody else was interested.” (Nurse, Practice N)  
Interestingly, there were still a substantial number of GPs in each practice who either did not 
participate at all, or only to a very limited degree, in screening. 
“A few nurses and one of the doctors really ran with it…. we tend to find in a larger practice 
we get varied levels of engagement.” (Practice Manager, Practice G) 
 
Proposition 4: Regular structured screening data reports, including number screened and whether 
newly diagnosed patients are treated according to guideline, increase overall motivation and quality 
Practices appreciated receiving regular screening data reports, including the number of people with 
AF, the number screened by each staff member and the proportion of AF patients treated according 
to guideline. In many cases, GPs had never seen their practice data presented in that way. In some 
cases, it led to quality improvement, e.g. review of management for AF patients who were not 
previously treated according to guideline. 
“From a practicing GP’s point of view, you need to keep an eye on these people [patients not 
eligible for OAC at the time of AF diagnosis] because as time goes by, they can drift into the 
category that probably does benefit from anticoagulant.”  (GP, Practice D) 
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“When I saw the data…my first reaction was that’s actually a really good study.” (Practice 
Manager, Practice I) 
These data reports often increased motivation, and facilitated internal competition:  
“Feedback’s always great and timely feedback is particularly important. It is lovely to have 
been able to receive timely feedback each month, and we have enjoyed the friendly 
competition within our team!” (GP 2, Practice C)  
“The nurses got really competitive because [the GP champion] kept telling them who’d done 
the most.” (Practice Manager, Practice G)  
“Just on the reporting...We’re very competitive so I love the fact that I’m leading the nursing 
team. Our nurse who has just come back from maternity leave is keen to see the next round 
of data so she can see her name up there” (Nurse, Practice C)  
Proposition 5: Clear protocols for follow-up of abnormal results are required for nurse-led screening to 
be successful 
Approximately 16-20% of iECG readings were abnormal (either unclassified or possible AF) and 
required at least some follow-up. Therefore, nursing teams performing screening need a clear and 
efficient protocol for dealing with abnormal screening results.  
“If we had worked it out with our GPs beforehand, and had a clear protocol of how to move 
forward, it would have saved us a bit of to-ing and fro-ing between the GPs and myself.” 
(Nurse, Practice I) 
This is particularly important in the context of a hierarchical general practice system, where nurses 
may not be empowered to take next steps for follow up without GP input.  
“A nurse can't tell the patient anything. The doctor can at least provide some insight into 
what the result means.” (Practice Manager, Practice I)  
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Proposition 6: screening for a shorter, more intense, period (eg during flu vaccination) worked well for 
practices with sufficient staff time allocated to screening. This required remuneration for screening 
About one quarter of practices found that screening patients intensively for a shorter period worked 
well. Perhaps it is easier to maintain motivation and ‘momentum’ for a shorter period. For example, 
screening during dedicated flu clinics worked well in practices where there was extra time allocated 
for nursing staff and a clear protocol for dealing with abnormal results. Providing remuneration for 
screening in the context of a fee-for-service primary care system was important, as it provided an 
incentive to allocate extra staff time to screening. 
“Thankyou also for being one of the rare research studies to have been aware enough of the 
pressures on primary care to have built practice remuneration into your research protocol.” 
(GP 1, Practice C) 
The main benefit of screening during flu vaccination was that it captured a high proportion of eligible 
patients who do not otherwise attend the practice regularly. 
“I think it’s…rolling it in as a systematic process, and then that means we are doing it once a year 
for everybody.” (GP, Practice E)  
When these factors were absent, practices felt they would not have time to screen during flu 
vaccination: 
“The nurses were seeing one patient every 7 minutes to do the flu shot and therefore didn't really 
get round to doing this.” (Practice Manager, Practice K)  
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Proposition 7: Participating in an AF screening program had broader benefits of improving AF 
knowledge and raising the profile of cardiovascular health in the practice 
More than half of the interviewees commented on how their knowledge of AF had improved as a 
result of participating in the study and that it had raised the profile of cardiovascular health in their 
practice.  
“It made me improve my ‘patter’ about AF. I got the statistics right in my head about risks 
per annum per patient and what we were doing to try and get them down, which helped my 
medicine.” (GP 2, Practice A)  
“When I do a study and I’m focused on a particular topic, it does help me to be more diligent 
and vigilant on that topic.” (GP 1, Practice C) 
“[Screening] is adding to our conversation about heart health”. (Nurse, Practice C)  
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Figure 2 - summary of 7 key propositions 
Phase 3: Refined program theory  
The refined program theory context, mechanism and outcome (CMO) configurations are presented 
in Figure 3. Contexts included factors related to the regulatory environment of general practice in 
Australia, such as practice nurse remuneration. Nine mechanisms were identified, and 7 short term 
outcomes were identified. Short term outcomes primarily related to behaviour change, motivation, 
and barriers and enablers to screening. Longer term outcomes were increasing the proportion of 
eligible people screened (and treated according to guideline), and ultimately preventing strokes. 
Individual practice screening data are presented in Table 1. This includes the number of patients 
screened and the proportion of eligible patients screened (across the whole practice, not just for 
GPs/nurses who participated in screening). In addition, links between these data and refined 
program theory CMO configurations are included. As can be seen, the 5 practices screening the 
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highest numbers and proportion of eligible patients have GP champions, an engaged nursing team 
with a leader and well-established protocols for following-up abnormal results.  
22 
 
 
Figure 3 – refined program theory. AF, atrial fibrillation; iECG, smartphone electrocardiograph; CPD, continuing professional 
development; QI, quality improvement 
 
23 
 
Table 1: individual practice screening data and links to refined program theory 
Site  Eligible 
patients 
screened (%) 
Eligible 
patients 
screened (n) 
Link to CMO configuration 
Practice A 
(rural) 
51% 611 
- senior GP champions  
- nurse leadership  
- internal competition 
- detailed QI reporting & improved prompt 
Practice B 
(rural) 
48% 473 
- senior GP champion 
- nurse-led, teamwork  
- detailed QI reporting & improved prompt 
Practice C 
(rural) 
43% 595 
- senior GP champion 
- nurse leadership 
- internal competition between nurses 
- detailed QI reporting & improved prompt 
Practice D 
(rural) 
42% 697 
- nurses screening intensively during flu vaccination clinic 
- detailed QI reporting & improved prompt 
Practice E 
(metro) 
33% 231 
- senior GP champion 
- nurses screened intensively during GP-led flu vaccination clinic 
Practice G 
(rural) 
28% 443 
- senior GP champion 
- internal competition between nurses 
- detailed QI reporting & improved prompt 
Practice F 
(metro) 
27% 322 - senior GP champion screening opportunistically 
Practice H 
(rural) 
20% 124 
- GP and nurses screening 
- very small practice 
- detailed QI reporting & improved prompt 
Practice I 
(metro) 
19% 690 
- senior GP champion 
- very large practice 
- dedicated preventive care nurses screening 
Practice J 
(metro) 
19% 263 - GP champion, nurse also screening opportunistically 
Practice K 
(metro) 
16% 120 - several GPs screening less intensively over longer period  
Practice L 
(rural) 
15% 69 
- very small nursing team 
- detailed QI reporting/improved prompt 
Practice M 
(rural) 
9% 102 - only 1 GP screening within medium-size practice 
Practice N 
(metro) 
6% 59 - mainly single practice nurse screening  
Practice O 
(metro) 
5% 66 - nurses screening opportunistically over longer period 
Practice P 
(metro) 
4% 55 - mainly 1 GP screening within large practice 
TOTAL 
SCREENED 
 
1,805 (metro) 
3,114 (rural) 
4,919 
(combined) 
 
Table Legend: CMO, context, mechanism, outcome; Metro, metropolitan; GP, general practitioner; QI, quality 
improvement. 
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DISCUSSION 
Summary of findings 
This evaluation identified and explained the circumstances in which an opportunistic AF screening 
program in general practice worked to increase the proportion of eligible people screened for AF. To 
our knowledge, this is the first realist evaluation to systematically link specific individual and 
practice-level mechanisms of action with program outcomes in relation to AF screening.  
The results suggest that key mechanisms for program success are practice-wide engagement driven 
by senior GP leadership and regular QI feedback, and high user acceptance of novel eHealth tools 
including an automated prompt to identify eligible patients. In some practices, undertaking intensive 
screening program over a shorter period (e.g. during annual flu vaccination) worked well, provided 
sufficient staff time was allocated and that there was a clear protocol for follow-up of abnormal 
results. 
Our initial program theory focussed on eHealth resources providing the mechanisms, but our refined 
theory found that mechanisms were also highly related to internal motivation. Therefore, while 
providing novel and efficient electronic tools was a helpful resource for motivated GPs and nurses, a 
more nuanced approach may be needed to encourage a broad uptake, especially by GPs, in each 
practice.  
Comparison with existing literature  
A number of previous studies have evaluated the feasibility of screening for AF using a single-lead 
rhythm strip to detect unknown AF in general practice (11, 22, 23, 33, 34). Similar issues in terms of 
barriers and enablers to AF screening were also described in a pharmacy screening program (35). As 
in this study, our previous pilot studies of AF screening in general practice also found that GPs and 
nurses really like the iECG device, and that nurses were very confident providing screening (22, 23). 
Guidelines and expert consensus statements now expressly state that AF screening may be 
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performed using an ECG rhythm strip (as an alternative to pulse palpation) (1, 5). The increased 
specificity and sensitivity of digital tools(13, 36) compared with pulse palpation(37) are important 
advantages of new technology. It is suggested that this should be considered in future guideline 
updates, as improved screening accuracy may reduce the need for specialist review of the diagnosis, 
and therefore improve patient management, providing timely and appropriate initiation of 
thromboprophylaxis with oral anticoagulant. However, as the guidelines do recommend 
echocardiographic assessment, and selection of a rate- or rhythm-control strategy, this will generally 
require referral to a specialist.  
This evaluation highlighted the importance of having a senior GP screening ‘champion’ together with 
a nursing team with a clear leader. While we previously noted the varied engagement in the 
screening process in the AF-SMART metropolitan study (11), it appeared engagement levels were 
generally higher in the rural practices. These practices almost all had a clear GP champion who was a 
senior member of the practice and a very engaged nursing team with clear leadership. This 
combination was highly influential for success. Previous studies have also emphasised the key role of 
an empowered ‘organisational change champion’ together with a ‘project champion’ in successfully 
implementing and sustaining quality improvement initiatives in primary care (38, 39).  
Frequent QI reporting provided motivation for practices. The AF-SMART metropolitan study found 
that the clinical audit data could be further improved (11). The rural practices also showed the 
benefits of more detailed, frequent QI reporting as part of an enhanced ‘audit and feedback’ system. 
These reports facilitated internal competition between GPs and nurses regarding screening numbers 
at several practices, as well as several examples where the treatment of newly diagnosed patients 
was reviewed based on the QI reporting. This is consistent with a 2003 Cochrane review which that 
found audit and feedback systems improve clinical performance (40), and also with a 2012 Cochrane 
review which found that the success of audit and feedback systems depends both on baseline 
performance and how feedback is provided (41). 
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Screening intensively for a shorter period of time (e.g. during flu vaccination) was an effective model 
in practices that were well prepared. This was similar to the results in our 2016 pilot study where 
nurses conducted AF screening during flu vaccination (23), which found that this method of 
screening could be very successful provided sufficient time was allocated and there was a clear 
protocol at the outset for follow up of abnormal results. AF screening during flu vaccination clinics 
has also been found to be feasible in the Netherlands (33) and is being piloted in the UK (42).   
Strengths and limitations 
Realist evaluation is a practical approach for understanding the real-world program constraints, such 
as time and structural limitations. In terms of data collection, it was a strength that all interviews 
were conducted by the same researchers, and the sample was representative and appropriate in 
that staff from all practices participated in the interviews.  
There were some limitations in the data collection. Our semi-structured interviews only captured a 
sample of each practice, and may not reflect the views of all GPs and nurses in that practice. 
However, significant bias is unlikely given the overall number of interviews conducted and that 
several staff (with varying levels of screening numbers) were interviewed from each practice. Also, 
we note that interviews can be potentially affected by participants' desire to be socially acceptable 
and a reluctance to criticise the project (43). However, we do not consider this would have been 
likely to affect the validity of the findings as the topic was not particularly emotive, interviews were 
framed as an opportunity to give feedback, the sampling strategy was diverse and the responses 
were relatively consistent. 
Practical implications 
While our study findings are strongly context-related, it is possible they could translate to different 
primary care interventions within and/or to other health systems internationally. These findings 
could be used by policymakers designing and implementing screening or QI programs in general 
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practice. In particular, our findings suggest that the identification of a senior GP ‘champion’ together 
with provision of audit and feedback data (including at the individual staff member level), may be 
useful mechanisms to support practice-wide motivation/engagement to implement various 
programs in general practice. The ubiquity of electronic medical records systems in general practice, 
together with clinical audit tools to efficiently extract and analyse data, will provide increasing scope 
for QI feedback in future programs. Training health professionals in the acquisition, interpretation 
and dissemination of QI data within the practice may play a key role in the future success of 
implementation programs in general practice. 
Conclusions 
Our realist evaluation suggests that introducing an AF screening program is likely to be successful in 
contexts where there is a senior GP ‘screening champion’, a clear protocol exists for abnormal 
results, and there is regular data reporting to staff. These contexts link to mechanisms around 
motivation, leadership, empowerment of nurses, and efficient screening systems. Together the 
contexts and mechanisms raise the profile of cardiovascular health in the practice and contribute to 
the longer-term outcomes of increasing the proportion of people screened (and treated) for AF, 
which is recommended by guidelines as a key strategy for the prevention of AF-related stroke. 
Future programs need to specifically work on strategies to increase internal motivation and thereby 
encourage a broader uptake of screening in general practice. 
List of abbreviations 
AF: atrial fibrillation 
GP: general practitioner 
ECG: electrocardiogram 
iECG: smartphone electrocardiogram 
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CHA2DS2-VA: C, congestive heart failure/left ventricular dysfunction; H, high blood pressure; A2, age 
older than 75 years; D, diabetes mellitus; S2, stroke/transient ischemic attack/thromboembolism; V, 
vascular disease (coronary artery disease, myocardial infarction, peripheral artery disease, aortic 
plaque); A, age 65 to 74 years 
AF-SMART studies: Atrial Fibrillation Screen, Management And Guideline Recommended Therapy 
studies 
CMO: context, mechanism, outcome. 
EDS: electronic decision support 
QI: quality improvement 
CPD: continuing professional development 
Flu: influenza 
IT: information technology 
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